MicroPort NeuroTech Limited (2172.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.

Industry: Medical - Devices
Sector: Healthcare
Headquarters: CN
CEO: Zhiyong Xie
Listed since: Jul 15, 2022
Employees: 547

Market position

Day range

Current HK$8.485

HK$8.435HK$8.68

52-week range

Current HK$8.485

HK$8.40HK$15.14

Open: HK$8.68
Previous close: HK$8.68
Volume: 973K; 0.41× average
Average volume: 2.4M; Average daily volume
Market cap: 4.94B HKD
Beta: -0.05; Market reference 1
50-day average: HK$9.4118; -9.85% below average
200-day average: HK$10.5421; -19.51% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 4.98B CNY
P/E (TTM): 22.68×
P/B (TTM): 2.32×
P/S (TTM): 5.4×
EV / EBITDA: 14.69×
Earnings yield: 3.22%
Free cash flow yield: 2.77%
Dividend yield: 1.65%

Profitability & efficiency

Gross margin: 73.46%
Operating margin: 37.67%
Net margin: 23.35%
Return on equity: 9.99%
Return on assets: 8.52%
Return on invested capital: 11.25%

Financial health

Debt / equity: 0.01×
Current ratio: 6.01×
Altman Z-score: 11.04
Piotroski F-score: 7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

770.02M CNY+1.08%

Operating income

264.98M CNY-18.92%

Net income

179.73M CNY-29.28%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	770.02M CNY	761.76M CNY	665.62M CNY	547.35M CNY	382.8M CNY
Cost of goods sold	204.33M CNY	205.84M CNY	153.83M CNY	154.35M CNY	84.45M CNY
Gross profit	565.69M CNY	555.93M CNY	511.79M CNY	393M CNY	298.35M CNY
Research and development	75.9M CNY	96.48M CNY	165.13M CNY	123.27M CNY	94.13M CNY
Selling, general, and administrative	230.79M CNY	188.3M CNY	166.87M CNY	154.46M CNY	116.47M CNY
Operating expenses	300.71M CNY	229.11M CNY	291.97M CNY	271.29M CNY	213.63M CNY
Interest income	15.2M CNY	15.87M CNY	16.57M CNY	9.97M CNY	3.96M CNY
Interest expense	1.56M CNY	3.53M CNY	3.46M CNY	99.28M CNY	45.2M CNY
Depreciation and amortization	74.02M CNY	40.64M CNY	56.09M CNY	42.18M CNY	31.72M CNY
Operating income	264.98M CNY	326.82M CNY	219.82M CNY	121.72M CNY	84.73M CNY
Net income	179.73M CNY	254.17M CNY	145.55M CNY	−21.77M CNY	24.17M CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 0%; 0 beats, 0 misses, 1 met estimate
Average EPS surprise: 0.00%; 1 comparable report
Latest EPS result: 0.18

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.16

2025 complete year-15.8% since 2024

2026 partial: HK$0.09

HK$0.19

2,024

HK$0.16

2,025

HK$0.09

2,026*

* Partial calendar year in the available dividend history.

Corporate action history

Action	Ex-dividend date	Details	Record date	Payment date
Dividend	Jul 2, 2026	HK$0.09Semi-Annual	Jul 3, 2026	Aug 21, 2026
Dividend	Sep 10, 2025	HK$0.05Semi-Annual	Sep 12, 2025	Sep 26, 2025
Dividend	Jul 2, 2025	HK$0.11Semi-Annual	Jul 4, 2025	Aug 22, 2025
Dividend	Sep 10, 2024	HK$0.08Semi-Annual	Sep 11, 2024	Sep 26, 2024
Dividend	Jun 28, 2024	HK$0.11Semi-Annual	Jul 2, 2024	Aug 22, 2024